Cargando…

A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG)

OBJECTIVE: To investigate the prevalence of histopathological subtypes, the clinical stage at presentation and treatment modalities in Polish patients with orbital lymphoma (OL) and to determine prognostic outcomes. METHODS: The retrospective study of 107 patients with OL treated in a 14‐year period...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalicińska, Elżbieta, Giza, Agnieszka, Zaucha, Jan Maciej, Giebel, Sebastian, Zimowska‐Curyło, Dagmara, Andrasiak, Iga, Spychałowicz, Wojciech, Wojnar, Jerzy, Balcerzak, Andrzej, Romejko‐Jarosińska, Joanna, Paszkiewicz‐Kozik, Ewa, Knopińska‐Posłuszny, Wanda, Rybka, Justyna, Jabłonowska, Paula, Wróbel, Tomasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939129/ https://www.ncbi.nlm.nih.gov/pubmed/36161781 http://dx.doi.org/10.1002/cam4.5223

Ejemplares similares

Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report
por: Drozd-Sokolowska, Joanna, et al.
Publicado: (2020)

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4
por: Walewski, Jan, et al.
Publicado: (2019)

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study
por: Kalicińska, Elżbieta, et al.
Publicado: (2020)

Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers
por: Jurczak, Wojciech, et al.
Publicado: (2015)

P017: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma
por: Taszner, Michal, et al.
Publicado: (2022)

Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis
por: Czyz, Anna, et al.
Publicado: (2013)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
por: Giza, Agnieszka, et al.
Publicado: (2023)

Multisystem Inflammatory Syndrome in Adults (MIS-A) Reported in Patient with Hematological Malignancy: A Case Report
por: Kalicińska, Elżbieta, et al.
Publicado: (2023)

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
por: Romejko-Jarosinska, Joanna, et al.
Publicado: (2022)

Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs
por: Paszkiewicz-Kozik, Ewa, et al.
Publicado: (2021)

The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
por: Jurczak, Wojciech, et al.
Publicado: (2015)

Elevated level of PLRG1 is critical for the proliferation and maintenance of genome stability of tumor cells
por: Choi, Hyunji, et al.
Publicado: (2023)

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
por: Topp, Max S., et al.
Publicado: (2022)

The first case of human autochtonous subconjunctival dirofilariosis in Poland and MALT lymphoma as possible consequence of this parasitosis
por: Borkowski, Piotr K, et al.
Publicado: (2015)

Prognostic Value of the Immunological Subtypes of Adolescent and Adult T-Cell Lymphoblastic Lymphoma; an Ultra-High-Risk Pro-T/CD2(−) Subtype
por: Ostrowska, Beata, et al.
Publicado: (2021)

T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
por: Gallamini, Andrea, et al.
Publicado: (2022)

Infection and expression of Toll-like receptors in lymphoid malignancy patients after autologous stem cell transplantation
por: Wicherska-Pawłowska, Katarzyna, et al.
Publicado: (2021)

Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation
por: Szumera-Ciećkiewicz, Anna, et al.
Publicado: (2020)

Endothelial Activation and Stress Index (EASIX) as an Early Predictor for Mortality and Overall Survival in Hematological and Non-Hematological Patients with COVID-19: Multicenter Cohort Study
por: Kalicińska, Elżbieta, et al.
Publicado: (2021)

Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion
por: Kaźmierczak, Maciej, et al.
Publicado: (2013)

RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1
por: Liu, Zhen, et al.
Publicado: (2022)

FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma
por: Gallamini, Andrea, et al.
Publicado: (2021)

Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
por: Gil, Lidia, et al.
Publicado: (2014)

Editor's Note to ‘Identification of peptide inhibitors of pre-mRNA splicing derived from the essential interaction domains of CDC5L and PLRG1’
Publicado: (2022)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
por: Wróbel, Tomasz, et al.
Publicado: (2023)

The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination
por: Świerkot, Jerzy, et al.
Publicado: (2022)

Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy
por: Kocurek, Anna, et al.
Publicado: (2016)

Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin – case study and brief literature review
por: Barańska, Marta, et al.
Publicado: (2017)

PB1915: THE MULTI-FACETED ROLE OF ORAL AND GUT MICROBIOME IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Paziewska, Magdalena, et al.
Publicado: (2023)

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2021)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Ozcan, Muhit, et al.
Publicado: (2023)

VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma
por: Wróbel, Tomasz, et al.
Publicado: (2013)

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases
por: Yu, Youxi, et al.
Publicado: (2022)

Clinical manifestations of diffuse large B-cell lymphoma in the skin and subcutaneous tissue a case series study
por: Dulik, Katarzyna, et al.
Publicado: (2020)

Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment
por: Biernat, Monika Maria, et al.
Publicado: (2021)

The Lymphomas
por: Hoskin, P J
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_blnp5ccnf36oonbcobk2llcm2j